Revelation Biosciences, Inc. · NASDAQ:REVB
Revelation Biosciences — Investor Presentation (March 2025)
22 slides from Revelation Biosciences's investor presentation, Mar 17, 2025
Slide 1: Rebalancing inflammation to optimize health
BIOSCIENCES > REVELATION Q\ Rebalancing inflammation to optimize health NASDAQ: REVB www.revbiosciences.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the w
Slide 3: Gemini Platform
Gemini™ Platform The Gemini! platform is based on the API] PHAD® — sss) Program Therapeutic Indication Discovery Phase 1 Phase 2 Phase 3 GEM-AKI Acute Kidney Injury — +4 GEM-CKD Chronic Kidney Diese 9§_ JD GEM-PSI Post Surgical Infection TD GEM-PBI Post Burn Infection i <=Zz Portfolio Multiple? | a)
Slide 4: Has Large Market Potential
Gemini Has Large Market Potential AKI $6 Billion 5M total patients CKD $9.25 Billion 37M total patients $19+ Billion PSI $3.125 Billion 6.25M total patients PBI $0.75 Billion 30k total patients 2 REVELATION BIOSCIENCES
Slide 5: How Gemini Works
How Gemini Works Reduced Preconditioned inflammation Recovery Gemini No Gemini No Recovery __ > to Longer Recovery Normal State Significant inflammation 2 REVELATION / BIOSCIENCES
Slide 6: Clinical and Preclinical Data
Clinical and Preclinical Data Demonstration of The Potential of Gemini in Target Indications 2 REVELATION / BIOSCIENCES /
Slide 7: Cytokine Upregulation in Healthy Humans Agree with Cytokines in Healthy Animals
Cytokine Upregulation in Healthy Humans Agree with Cytokines in Healthy Animals Cytokine Upregulation in Humans (Phase 1 study data in healthy volunteers) IL1-RA IL-10 NGAL Neutrophil 140000, Ld 12 12 n 1000 = 2 "0 = 10 100000 S 2 a i i 80000 ¥ ” 7 = 0 I z a | z = men — ” ‘ —_ ‘ i 20000 2 é —_ 3 3 3
Slide 8: Induced Cytokines Protects Against AKI in Preclinical Ischemia/Reperfusion Model
Gemini Induced Cytokines Protects Against AKI in Preclinical Ischemia/Reperfusion Model Change in Creatinine Change in BUN 4 p<0.04 p<0.02 p<0.02 wn . ° 140 -_eor— = 35 co 120 9 0 2 3 3 Fa 100 | ~ 25 q SN 20 i as > 5 = i zs 3 60 H + 1s ; ot : i } 40 Ba ss. 06d _ | — = aa = a 2.24 heshom 24h post -Ou
Slide 9: Induced Cytokines Protects Against Kidney Scarring in Preclinical UUO CKD Model
Gemini Induced Cytokines Protects Against Kidney Scarring in in Preclinical UUOt CKD Model on * t t t 6% 2 T 5 5% T $ I . I x I aa I — I 1% UUuO Positive Gemini Gemini Gemini 0% Sham Control Control {0.1mg/kg) (0.3 mg/kg) 0.9 mg/kg) * p< 0.05 vs Sham 1p <0.05 vs UUO control * Gemini treatment Gemini
Slide 10: Induced Cytokines Protects Against Severe Systemic Infection
Gemini Induced Cytokines Protects Against Severe Systemic Infection S. Aureus Clearance Survival after Intravenous S. aureus Spleen Kidney 10°. 10°. 1007 ne * i] 4 Vehicle 10°97 a ® 2 8 + PHAD 106. & 4 * 2 2 2 10° 5 60 5 > 105 > Cary a 5 Se 5 oye tee 5” 10! ror ¢ iot 108 : gE % 5. OF mw 3 wi 5 024 6
Slide 11: PRIME Phase 1b Clinical Study in CKD Patients Ongoing
PRIME Phase 1b Clinical Study in CKD Patients Ongoing PRIME — PRotective IMmunostimulatory Evaluation A Phase 1b, Randomized, Placebo Controlled, Single Blind, Single-Ascending Dose in Stage 3 and Stage 4 CKD Patients Design * Single dose, dose escalation * 5 cohorts, 8 subjects per cohort 1:4 place
Slide 12: Sample Collection and Analysis for attenuated immune response
Sample Collection and Analysis for attenuated immune response Collect whole \ blood 4 —— on. AN 2and 24 \ - hours after XN subject has \ been dosed Centrifuge blood between Primed and Placebo ESD ag Measure delta SE pheral Blood “Assay PBMCs with Mononuclear Cell and without TLR4 agonist (HMGB-1 and
Slide 13: Priming attenuates inflammation in human PBMCs ex vivo
Gemini priming attenuates inflammation in human PBMCs ex vivo Priming peripheral blood mononuclear cells (PBMCs, white bar) with Gemini reduces the pro-inflammatory response (IL- 1B), and maintains the anti-inflammatory response (IL-1RA) relative to the stimulation observed for HMGB-1 or LPS alone (
Slide 14: Financial Overview
Financial Overview / \ 2 REVELATION /— \ BIOSCIENCES s Pc
Slide 15: Financial Summary
Financial Summary 2 REVELATION / BIOSCIENCES Relevant Market Information (as of 3/14/2025) Stock Price Common Stock Outstanding Market Cap Fully Diluted Share Count! Balance Sheet and P&L (as of 12/31/2024) Cash Stockholders’ Equity Quarterly Burn Rate $3.40 905,228 $3.1M 2,813,462 orronte wit sce p
Slide 16: Why You Should Invest in REVB
Why You Should Invest in REVB * Enormous market potential ($19+ Billion) ° Experienced Management with multiple FDA approvals (8 approvals) * Rapidly derisking the Gemini platform ¢ Product candidates that can significantly help many people 2 REVELATION / BIOSCIENCES / 16
Slide 17: Thank You!
2 REVELATION / BIOSCIENCES Thank You! For more information, please visit www.revbiosciences.com vv
Slide 18: Supplemental Information
Supplemental Information
Slide 19: How Gemini Works
How Gemini Works * Gemini stimulates TLR4 via the TRIF pathway which is the anti-inflammatory pathway resulting in the upregulation of multiple beneficial cytokines Gemini * These beneficial cytokine train the immune cells to respond faster to stress and to better tolerate stress resulting in less i
Slide 20: Increase Protective and Decrease Inflammatory Cytokines in UUO CKD Model
Gemini Increase Protective and Decrease Inflammatory Cytokines in UUO CKD Model TGF-B IL-10 NGAL 1600 . . 4000 . . . 4500 * . . ia 4000 00 12000 3500 1200 = 10000 be ols} —4 8 ome, . 2500 T wo LT + t : 200 . | ol ee ~ _ = + 1500 = & é g x 000 : t x ; # Las | 20 . I = s00 ; = ° oe ag OGp 1 Sham SGp 2
Slide 21: Decreases Inflammation in an Ischemia/Reperfusion AKI Model
Gemini Decreases Inflammation in an Ischemia/Reperfusion AKI Model Urinary CRP at 24 hours 000 p<0.01 3500 7 3000 2000 1500 iB 1000 Urinary IL-6 at 24 hours p<0.05 |Sham-24hr 20 mg/kg-24hr © 0.35 mg/kg -24hr Serum CRP at 72 hours 1600 p<0.01 2 5 4s ° Neutrophilic Inflammation at 72 hours p<0.02 a5 ©
Slide 22: Reduces Kidney Damage in an Ischemia/Reperfusion AKI Model
Gemini Reduces Kidney Damage in an Ischemia/Reperfusion AKI Model Acute Cortical Tubular Necrosis Medullary Tubular Necrosis 0 5 p<0.01 5 Bos = re p<0.02 a 48 4 ——— N 4 a es z S35 5 z 7 5 as | 25 £ 2 i 2 . > 15 ed s 1 ° ° 1 = . 0.5 ° Bos ° a Sham 50 mg/kg 00.35 mg/kg * Gemini reduced injury to the c
Revelation Biosciences — Investor Presentation (March 2025) on 6ix